Alcohol and Alcoholism Vol. 35, No. 2, pp. 202-209, 2000
© 2000 Medical Council on Alcoholism
ACAMPROSATE AND RELAPSE PREVENTION IN THE TREATMENT OF ALCOHOL DEPENDENCE: A PLACEBO-CONTROLLED STUDY
Institute of Pharmacology and
1 Institute of Psychiatry, Università Cattolica del Sacro Cuore, Rome,
2 c/o HyperPhar, via Pascoli 60, Milan, Italy,
3 Lipha-Merck 34–37 rue Saint Romain, Lyon and
4 c/o Lipha-Merck, Lyon, France
Received 6 April 1998; first review notified 14 October 1999; accepted 18 October 1999
The objective of this study was to compare acamprosate with placebo in the treatment of alcohol-dependent patients during a 6-month post-detoxification treatment and a 3-month medication-free follow-up. Patients (n = 330) were detoxified and randomized to treatment with acamprosate (1998 mg/day) or placebo within an out-patient programme including medical counselling, psychotherapy and self-help groups. The main outcome criterion was drinking behaviour as assessed by: abstinence/relapse ratio, cumulative abstinence duration (CAD) and the period of continued abstinence. Anxiety, depression and craving were also monitored. Intention to treat (ITT) statistical principles were followed. Twenty-five per cent of patients dropped out over the first 6 months. At the end of the treatment period, the abstinence rate was 57.9% for acamprosate and 45.2% for placebo (P = 0.03). The CAD was 110 ± 77 days for acamprosate and 89 ± 77 days for placebo (P = 0.016). Patients on acamprosate had a higher continuous abstinence rate and experienced less severe relapses. No differential effect was noted for anxiety, depression or craving. Treatment remained positive, but not significant, 3 months after termination of study medication. No significant difference in adverse events was noted between treatment groups. Acamprosate treatment over 180 days was consistently more effective than placebo to maintain abstinence and to diminish relapse severity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 B. J. Mason Acamprosate for Alcohol Dependence: An Update for the Clinician Focus, September 1, 2006; 4(4): 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hammarberg, P. Wennberg, O. Beck, and J. Franck A COMPARISON OF TWO INTENSITIES OF PSYCHOSOCIAL INTERVENTION FOR ALCOHOL DEPENDENT PATIENTS TREATED WITH ACAMPROSATE Alcohol Alcohol., May 1, 2004; 39(3): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chick, P. Lehert, and F. Landron Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence? J Psychopharmacol, December 1, 2003; 17(4): 397 - 402. [Abstract] [PDF]
|
|
|
|
 |
|
 G. P Overman, C. J Teter, and S. K Guthrie Acamprosate for the Adjunctive Treatment of Alcohol Dependence Ann. Pharmacother., July 1, 2003; 37(7): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Namkoong, B.-O. Lee, P.-G. Lee, M.-J. Choi, and E. Lee ACAMPROSATE IN KOREAN ALCOHOL-DEPENDENT PATIENTS: A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY Alcohol Alcohol., March 1, 2003; 38(2): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rubio, M. A. Jimenez-Arriero, G. Ponce, and T. Palomo NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT Alcohol Alcohol., September 1, 2001; 36(5): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Kranzler PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH Alcohol Alcohol., November 1, 2000; 35(6): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chick, H. Howlett, M. Y. Morgan, B. Ritson, and f. t. U. I. UNITED KINGDOM MULTICENTRE ACAMPROSATE STUDY (UKMAS): A 6-MONTH PROSPECTIVE STUDY OF ACAMPROSATE VERSUS PLACEBO IN PREVENTING RELAPSE AFTER WITHDRAWAL FROM ALCOHOL Alcohol Alcohol., March 1, 2000; 35(2): 176 - 187. [Abstract] [Full Text] [PDF]
|
|